Composition for enhancing immunity
A composition of Angelica root and Peony extracts with polysaccharide isolates addresses the challenge of weakened immunity by boosting NK cell activity and immune-related cytokines, effectively enhancing innate immunity.
Patent Information
- Application Number
- PCT/KR2024/008640
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-21
- Filing Date
- 2024-06-21
- Publication Date
- 2024-12-26
AI Technical Summary
Modern lifestyle factors such as stress, lack of exercise, and unbalanced diets often lead to weakened immunity, and existing research has not adequately explored the immune-enhancing effects of Angelica root and Peony extracts, particularly in combination with polysaccharide isolates, to strengthen innate immunity.
A composition comprising mixed extracts of Angelica root, Angelica gigasia, and Peony root, along with their polysaccharide isolates, is used as an active ingredient to enhance immunity, characterized by increased NK cell activity, WBC count, spleen cell density, and immune-related cytokine production, particularly for innate immunity.
The composition significantly enhances immune function by increasing NK cell activity, WBC count, spleen cell proliferation ability, and immune-related cytokine production, effectively improving innate immunity and serving as an immune enhancer.
Smart Images

Figure KR2024008640_26122024_PF_FP_ABST
Abstract
Description
Composition for enhancing immunity
[0001] The present invention relates to an immune-enhancing composition comprising a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia japonica and a polysaccharide isolate thereof, or a fraction thereof, as an active ingredient.
[0002]
[0003] Immunity is a vital biological defense system that protects against diseases caused by external pathogens. The COVID-19 pandemic has highlighted the importance of the functionality and effectiveness of the immune response in combating viral infections.
[0004] The immune system can be divided into the innate immune system, the nonspecific immune system, and the specific immune system. The innate immune system (first line of defense) refers to the anatomical and physiological elements that block all invaders, including microorganisms, regardless of their type. The nonspecific immune system (second line of defense) is a defense system composed of phagocytes that eliminate invaders that have overcome the innate immune system and entered the body. The specific immune system (tertiary line of defense) is comprised of lymphocytes. The specific immune system is a highly developed immune system with memory and the ability to distinguish between self and non-self. Furthermore, white blood cells constitute the second or third line of defense, responding to foreign substances that have breached the first line of defense and entered the body. During bacterial or viral infections or inflammatory responses, the regulation of macrophage and lymphocyte activity plays a pivotal role in determining the therapeutic efficacy of pharmaceuticals. Immune function modulation is categorized into immune function enhancement and immune function suppression. Immunoenhancement refers to contributing to the enhancement of a weakened immune system, including the enhancement of normal immune function. Immune suppression refers to the suppression of excessive immune responses. It is known that cytokines and nitric oxide, immune factors overproduced by macrophages in response to stimulation by external toxic factors such as LPS, induce chronic inflammation and, as a result, chronic inflammation-related diseases. However, increasing the immune factors produced by normal macrophages through natural products is known to enhance immunity and suppress diseases associated with immunosuppression.
[0005] Immunity can be broadly classified into two types: innate immunity, which we are born with, and acquired immunity, which we acquire through adaptation to life.
[0006] Innate immunity, also known as natural immunity, is characterized by a non-specific response to antigens and lack of specific memory. The innate immune system includes skin and mucous tissues that block the invasion of antigens, acidic stomach acid, and complement present in the blood. Cells include macrophages and polymorphonuclear leukocytes, which are responsible for phagocytosis, and NK cells, which can kill infected cells. In fact, most infections are defended against by this innate immunity. Acquired immunity, also known as adaptive immunity, can remember the antigen that first invaded and respond specifically to it again, effectively eliminating it, and serves to reinforce the innate immunity.
[0007] The field of innate immunity has recently been attracting attention, as activating innate immunity can be a fundamental method of preventing various infectious pathogens. Furthermore, a strong immune system reduces the risk of disease, facilitates rapid recovery from illness, and maintains a healthy state. Therefore, maintaining a healthy immune system is crucial for maintaining health and extending lifespan.
[0008] However, if we look at the lifestyle habits of modern people, stress, lack of exercise, irregular daily rhythm, unbalanced diet, smoking, etc. can easily weaken the immune system. In addition, various pollutions are prevalent in the living environment, which also has many factors that weaken the immune system. Therefore, modern people must make efforts to strengthen the immune system. While research on natural products to enhance immunity has been conducted (e.g., patent document 1), angelica, cnidium, and peony have not been sufficiently studied. In particular, the effect of strengthening innate immunity using a mixed extract of angelica, cnidium, and peony has not been studied.
[0009] Accordingly, the present inventors have confirmed that a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia japonica and a mixture of polysaccharide isolates thereof, or a fraction thereof, increases body weight, increases WBC count, restores spleen cell density, increases spleen cell proliferation, and increases immune-related cytokines, and particularly significantly increases NK cell activity in relation to innate immunity, thereby confirming that it can be used in a food composition for enhancing immunity, thereby completing the present invention.
[0010]
[0011] The purpose of the present invention is to provide an immune-enhancing composition comprising a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof, or a fraction thereof, as an active ingredient.
[0012]
[0013] To solve the above problem,
[0014] An embodiment of the present invention embodying the present invention is an immune-enhancing composition comprising a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof, or a fraction thereof, as an active ingredient.
[0015]
[0016] As a specific example, the immunity is characterized as being innate immunity, acquired immunity, or a combination thereof.
[0017] As another specific example, the extract is characterized in that it is extracted with a solvent selected from the group consisting of water, straight-chain or branched alcohols having 1 to 6 carbon atoms, organic solvents, and mixed solvents thereof.
[0018] As another specific example, the extract is characterized by containing Angelica gigas, Cnidium officinalis and Peony root in a weight ratio of 1:1.2 to 3:1.2 to 3.
[0019] As another specific example, the mixed extract is characterized by being a mixed extract of Chinese angelica, Chinese cnidium or Cnidium officinalis and peony root.
[0020] As another specific example, the polysaccharide isolate is characterized in that it is an ethanol polysaccharide.
[0021] As another specific example, the ethanol is characterized as being 95% ethanol.
[0022] As another specific example, the fraction is characterized in that it is a water or ethanol fraction of the mixture.
[0023] As another specific example, the water fraction or ethanol fraction is characterized by having T cell proliferative ability.
[0024] As another specific example, the water fraction or ethanol fraction is characterized by having a T cell proliferation ability of 130 to 160% at a concentration of 400 to 500 μg / ml.
[0025]
[0026] As another specific example, the mixture is characterized by containing a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof in a ratio of 60 to 70:30 to 40.
[0027] As another specific example, the mixture or its fraction is characterized in that it is comprised in an amount of 0.001 to 90 wt% based on the total weight of the composition.
[0028]
[0029] As another specific example, the mixture or a fraction thereof is characterized by increasing NK cell activity.
[0030] As another specific example, the mixture or a fraction thereof is characterized by weight gain, increased WBC count, restoration of splenocyte density, increased splenocyte proliferation, and increased immune-related cytokines.
[0031] As another specific example, the cytokine is characterized by being at least one selected from the group consisting of IL-2, IFN-γ, IL-4, IL-10, TNF-α, IL-12, and IL-6.
[0032] As another specific example, the composition is characterized in that it is a food composition.
[0033] As another specific example, the food composition is characterized in that it is manufactured as a powder, granules, tablets, capsules, syrup or beverage.
[0034]
[0035] Another aspect of the present invention embodying the present invention is the use of a composition comprising a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof, or a fraction thereof, as an active ingredient, for enhancing immunity.
[0036] Another aspect of the present invention embodying the present invention is a method for enhancing immunity, comprising a step of treating or administering a composition comprising a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof, or a fraction thereof, as an active ingredient.
[0037]
[0038] According to the present invention, a composition comprising a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof or a fraction thereof as an active ingredient increases body weight, increases WBC count, restores spleen cell density, increases spleen cell proliferation ability and increases immune-related cytokines, and particularly significantly increases NK cell activity in relation to innate immunity, so that it can be applied as an immune enhancer or a food composition for enhancing immunity.
[0039]
[0040] Figure 1 shows the in vitro spleen cell proliferation ability of a mixture according to one manufacturing example of the present invention.
[0041] Figure 2 shows the degree of spleen cell cytokine expression in vitro of a mixture according to one manufacturing example of the present invention.
[0042] Figure 3 shows the in vitro T cell proliferation ability of a fraction of a mixture according to one manufacturing example of the present invention.
[0043] Figure 4 is a schematic diagram showing the overall experimental period for inducing immunosuppression during the production of an animal model according to one manufacturing example of the present invention and administering a mixture (HG) according to one embodiment of the present invention.
[0044] Figure 5 shows the results of confirming weight loss and immunosuppression induction after CTX administration according to one manufacturing example of the present invention and confirming the in vivo weight recovery ability when administering a mixture (HG) according to one embodiment of the present invention.
[0045] Figure 6 confirms the induction of immunosuppression after CTX administration according to one manufacturing example of the present invention and confirms the in vivo WBC recovery ability when administering a mixture (HG) according to one manufacturing example of the present invention.
[0046] Figure 7 confirms an increase in in vivo NK cell activity when a mixture (HG) according to one manufacturing example of the present invention is administered.
[0047] Figure 8 shows that the in vivo spleen cell density is restored when a mixture (HG) according to one manufacturing example of the present invention is administered.
[0048] Figure 9 shows that the expression of in vivo immune-related cytokines increases when a mixture (HG) according to one manufacturing example of the present invention is administered.
[0049] Figure 10 shows the in vivo spleen cell proliferation ability confirmed upon administration of a mixture (HG) according to one manufacturing example of the present invention.
[0050]
[0051] Each description and embodiment disclosed herein may also be applied to other descriptions and embodiments. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. Furthermore, the scope of the present invention is not limited by the specific descriptions described below.
[0052] Furthermore, those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments of the invention described in this application. Furthermore, such equivalents are intended to be encompassed by the present invention.
[0053] Additionally, throughout the specification of this application, when a part is said to "include" a certain component, this does not mean that other components are excluded, but rather that other components may be included, unless otherwise specifically stated.
[0054]
[0055] Hereinafter, the present invention will be described in more detail.
[0056] The present invention is based on the discovery that a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof, or a fraction thereof, increases body weight, increases WBC count, restores spleen cell density, increases spleen cell proliferation, and increases immune-related cytokines, and particularly significantly increases NK cell activity in relation to innate immunity, thereby enhancing immunity and thus can be utilized as an immune enhancer and immune tonic.
[0057]
[0058] An aspect of the present invention for achieving the above object provides an immune-enhancing composition comprising a mixture of a mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof, or a fraction thereof, as an effective ingredient.
[0059]
[0060] In the present invention, the term “Dang-Gwi” refers to the dried root of Chinese Angelica (Angelica sinensis (Oliv.) Diels), which is distinguished from the root of Korean Angelica gigas Nakai and Japanese Angelica acutiloba (Siebold. & Zucc.) Kitag. or Hokkaido Angelica (Angelica acutiloba (Siebold. & Zucc.) Kitag. var. sugiyamae Hikino). Chinese Angelica has warm energy and a sweet and very flavor, and generally, Chinese Angelica is sweeter and less spicy than True Angelica. The efficacy of Chinese Angelica is a blood-replenishing effect that produces blood when there is a deficiency of blood, and Angelica made from the root of Chinese Angelica has an excellent blood-replenishing effect. However, Angelica gigas, made from the root of the Angelica gigas, excels at promoting blood circulation rather than its blood-nourishing properties. It also has strong anticancer and antihypertensive effects. Pharmacologically, Angelica gigas is known to promote coronary blood flow and stimulate red blood cell production.
[0061] In the present invention, the term “Cheon-gung” refers to Chinese Cheon-gung (Ligusticum chuanxiongHort.) or Cnidium officinale, which is a perennial herb of the Apiaceae family, Umbelliferous order, and dicotyledonous group, and is commonly cultivated as a medicinal plant. It has sedative, analgesic, and tonic effects, and is used to treat headaches, anemia, and gynecological diseases. The rhizome is dug up from September to November, the leaves and stems are removed, dried in the sun, and then boiled and consumed, or used in the form of pills or powders.
[0062] In the present invention, the term "peony (Paeonia lactifloraPallas)" refers to a perennial herb of the Paeoniaceae family and Paeonia genus that grows in mountainous areas, and is used for horticultural purposes due to its beautiful flowers. In addition, the root is used as a medicinal herb for pain, abdominal pain, menstrual cramps, amenorrhea, hematemesis, anemia, bruises, etc. In China, it was cultivated as an ornamental plant as early as the Qin and Ming Dynasties, and its cultivation history is longer than that of peonies. Dozens of varieties were recorded during the Song and Qing Dynasties, and it is distributed in Korea, Mongolia, East Siberia, etc.
[0063] In the present specification, the peony may include one or more selected from the group consisting of peony, white peony, red peony, yellow peony, and true peony, and may be used without limitation regardless of the processing method.
[0064] The above-mentioned angelica, cnidium and peony root can be purchased commercially or used without restriction if collected or cultivated in nature.
[0065]
[0066] In the present invention, the term "extract" refers to a mixed extract containing the above-mentioned Angelica gigas, Cnidium officinalis and Paeonia lactiflora, and the above-mentioned mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora can be extracted from various organs of natural, hybrid and mutant plants, and specifically, can be extracted from roots, aerial parts, stems, leaves, flowers, body of fruit, peel of fruit, as well as plant tissue cultures.
[0067] The above "mixed extract" is a mixed extract containing all of Angelica gigas, Cnidium officinalis, and Peony root, and may be an extract obtained by first mixing the three substances and then extracting them together, or an extract obtained by extracting each substance individually and then mixing the extracts, and any other mixed extract manufactured by a known method capable of manufacturing a mixed extract is included without limitation.
[0068] The above extract may be obtained by extracting the pulverized product of each component with a solvent selected from the group consisting of water, straight-chain or branched alcohols having 1 to 6 carbon atoms, organic solvents, and mixed solvents thereof, but is not limited thereto. In addition, the extraction temperature may be in the range of 20°C to 100°C, and the extraction period may be an extract extracted using an extraction method such as hot water extraction, cold immersion extraction, reflux cooling extraction, or ultrasonic extraction for about 1 hour to 10 days, but is not limited to the extraction temperature, extraction period, or extraction method.
[0069] If the solvent of the above extract is water, it may include a cold water extract or a hot water extract.
[0070] The organic solvent is not particularly limited, and may be a polyhydric alcohol such as glycerol, ethylene glycol, propylene glycol, 1,3-butylene glycol, a hydrocarbon solvent such as methyl acetate, ethyl acetate, benzene, n-hexane, diethyl ether, dichloromethane, chloroform, and a non-polar organic solvent such as petroleum ether, methyl acetate, benzene, hexane, chloroform, methylene chloride, dimethyl ether, ethyl acetate, and the like.
[0071] The above solvent may also include an aqueous solution of an organic solvent, the concentration of which is not particularly limited, but may be 1 to 99% (v / v), specifically 60 to 98% (v / v), more specifically 80 to 95% (v / v), and even more specifically 95% (v / v).
[0072] The above extract may include an extract, a diluted or concentrated extract, a dried product obtained by drying the extract, or a modified or purified product thereof.
[0073] The above extract may contain Angelica gigas, Cnidium officinalis and Peony root in a weight ratio of 1 to 10:1 to 10:1 to 10, specifically in a weight ratio of 1 to 5:1 to 5:1 to 5, more specifically in a weight ratio of 1:1.2 to 3:1.2 to 3, even more specifically in a weight ratio of 1:1.3 to 2:1.2 to 2, even more specifically in a weight ratio of 1:1.4 to 1.7:1.2 to 1.6, even more specifically in a weight ratio of 1:1.5 to 1.7:1.2 to 1.5, even more specifically in a weight ratio of 1:1.6 to 1.3.
[0074]
[0075] As a specific example, the extract may be a mixed extract containing Chinese Angelica, Chinese Cnidium officinalis or Cnidium officinalis and Peony root in a weight ratio of 1:1.6:1.3.
[0076] As a specific example, the extract may be a mixed extract containing Chinese angelica, Chinese cnidium officinalis and peony root in a weight ratio of 1:1.6:1.3.
[0077]
[0078] The extract of the present invention may optionally include an extract of a known natural product or a known ingredient that promotes or strengthens immunity.
[0079]
[0080] In the present invention, the term "polysaccharide isolate" includes a polysaccharide precipitated by adding a solvent to the mixed extract of Angelica gigas, Cnidium officinalis and Paeonia lactiflora, wherein the polysaccharide is also called a polysaccharide and may include one or more polysaccharides.
[0081] The method for obtaining the polysaccharide isolate in the present invention is not particularly limited and can be performed according to a method commonly used in the art. A non-limiting example of the method may be a polysaccharide isolate obtained from the extracts of Angelica gigas, Cnidium officinalis, and Paeonia japonica of the present invention by treating the extracts with a predetermined solvent, and specifically, may be a polysaccharide isolate produced by adding an organic solvent to the extracts of Angelica gigas, Cnidium officinalis, and Paeonia japonica of the present invention, but is not limited thereto.
[0082] In the present invention, the type of solvent used to obtain the polysaccharide isolate is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the solvent include water, a straight-chain or branched alcohol having 1 to 6 carbon atoms, an organic solvent, or a mixed solvent thereof, which may be used alone or in combination of one or more, but are not limited thereto. In addition, the organic solvent may be at least one selected from the group consisting of dichloromethane, diethyl ether, chloroform, and ethyl acetate, but are not limited thereto.
[0083] Specifically, the polysaccharide isolate may be an ethanol polysaccharide, and more specifically, may be a 95% ethanol polysaccharide.
[0084]
[0085] In the present invention, the term "mixture" means a mixture obtained by mixing the extracts of Angelica gigas, Cnidium officinalis, and Paeonia lactiflora prepared in the present invention and the polysaccharide isolates obtained by treating each of the extracts with a predetermined solvent, and the mixing ratio is not particularly limited.
[0086] The composition can achieve significantly superior effects by combining extracts of each of the above plants and their polysaccharide isolates, compared to a composition comprising only one plant extract, polysaccharide isolate, or polysaccharide. In addition, the composition can exhibit significantly superior immune enhancement or strengthening effects compared to a composition comprising plant extracts, polysaccharide isolates, or polysaccharides other than Angelica gigas, Cnidium officinalis, and Paeonia japonica.
[0087] When the above mixture is a mixture of an extract and a polysaccharide isolate, the extract and the polysaccharide isolate may be included in a weight ratio of about 40 to 80:20 to 60, specifically 45 to 75:25 to 55, more specifically 50 to 70:30 to 50, even more specifically 60 to 70:30 to 40, and even more specifically 60:40, but is not limited thereto.
[0088]
[0089] In the present invention, the term "fraction thereof" means a result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture containing various components.
[0090] The fractionation method for obtaining the above-described fraction in the present invention is not particularly limited and may be performed according to a method commonly used in the art. A non-limiting example of the above-described fractionation method may be a fraction obtained by treating a mixture of the extracts of Angelica gigas, Cnidium officinalis, and Paeonia lactiflora of the present invention and their polysaccharides with a predetermined solvent.
[0091] In the present invention, the type of fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fractionation solvent include water, a straight-chain or branched alcohol having 1 to 6 carbon atoms, an organic solvent, or a mixed solvent thereof, which may be used alone or in combination of one or more, but are not limited thereto. In addition, the organic solvent may be at least one selected from the group consisting of dichloromethane, diethyl ether, chloroform, and ethyl acetate, but are not limited thereto.
[0092] Specifically, it may be a fraction produced by adding water or ethanol to a mixture of the extracts of Angelica gigas, Cnidium officinalis and Paeonia japonica and the polysaccharide isolates thereof of the present invention, and more specifically, a water fraction or ethanol fraction of a mixture of the extracts of Angelica gigas, Cnidium officinalis and Paeonia japonica and the polysaccharide isolates thereof.
[0093] More specifically, it may be a water fraction of a mixture of extracts of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and polysaccharide isolates thereof.
[0094] The water fraction or ethanol fraction of the mixture of the present invention may be characterized by having a T cell proliferative ability, and specifically, when the water fraction or ethanol fraction of the mixture of the present invention is at a concentration of 400 to 500 μg / ml, it may be characterized by having a T cell proliferative ability of 130 to 160%, more specifically, 135 to 155%.
[0095]
[0096] The mixture of extracts and polysaccharide isolates of Angelica gigas, Cnidium officinalis and Paeonia japonica or fractions thereof may be included in an amount of 0.0001 to 90 wt% based on the total weight of the composition, and specifically, the mixture or fractions thereof may be included in an amount of 30 to 80 wt% based on the total weight of the composition, more specifically, 35 to 70 wt%, and even more specifically, 40 to 65 wt%, but is not limited thereto.
[0097]
[0098] The mixture of extracts and polysaccharide isolates of the above-mentioned Angelica, Cnidium officinalis and Paeonia lactiflora or fractions thereof can increase NK cell activity.
[0099] The above term, NK cell, is known to function in the spleen and bone marrow and regulate innate immunity in the body, and NK cell activity can be measured by IFN-γ expression.
[0100] In addition, the mixture of extracts and polysaccharide isolates of Angelica gigas, Cnidium officinalis and Paeonia lactiflora or fractions thereof can increase body weight, increase WBC count, restore spleen cell density, increase spleen cell proliferation ability and increase immune-related cytokines.
[0101] The above immune-related cytokine may be at least one selected from the group consisting of IL-2, IFN-γ, IL-4, IL-10, TNF-α, IL-12, and IL-6.
[0102]
[0103] In the present invention, the term “improvement” means applying a mixture of extracts and polysaccharide isolates of Angelica gigas, Cnidium officinalis and Paeonia lactiflora of the present invention or a fraction thereof to a composition to enhance immunity, strengthen immunity or enhance immunity.
[0104]
[0105] The above composition may be a mixture of extracts and polysaccharide isolates of Angelica gigas, Cnidium officinalis and Paeonia lactiflora, or fractions thereof, added to a food composition for the purpose of enhancing, improving, enhancing or strengthening immunity, and the food composition may be a health functional food composition.
[0106] The above food composition may include a food-wise acceptable carrier.
[0107] The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food, and food additives, and the food composition of the above types can be manufactured in various forms according to conventional methods known in the art.
[0108] When using a mixture of extracts and polysaccharide isolates of Angelica gigas, Cnidium officinalis, and Paeonia japonica, or fractions thereof as a food additive, the mixture of extracts and polysaccharide isolates of Angelica gigas, Cnidium officinalis, and Paeonia japonica, or fractions thereof, may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The amount of the active ingredients may be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). Generally, when manufacturing a food or beverage, the mixture of extracts and polysaccharide isolates of Angelica gigas, Cnidium officinalis, and Paeonia japonica, or fractions thereof, is added in an amount of 0.0001 to 90 wt%, preferably 0.001 to 50 wt%, of the raw material composition. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be used below the above range.
[0109] There are no specific restrictions on the types of the above foods. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and can include all health foods in the conventional sense.
[0110] The health beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, like conventional beverages. The natural carbohydrates mentioned above include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used. The proportion of the natural carbohydrate may generally be about 0.001 to 50 parts by weight, and specifically about 0.01 to 30 parts by weight, per 100 parts by weight of the composition of the present invention.
[0111] In addition to the above, the composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. The proportion of these additives is not particularly important, but is typically selected from the range of 0.01 to 30 parts by weight per 100 parts by weight of the composition of the present invention. In addition, the composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. The proportion of this fruit pulp is not particularly important, but is typically selected from the range of 0.01 to 30 parts by weight per 100 parts by weight of the composition of the present invention, and these components may be used independently or in combination.
[0112]
[0113] Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to exemplify the present invention, and the scope of the present invention is not limited by these examples, as will be apparent to those skilled in the art to which the present invention pertains.
[0114]
[0115] Example 1. Preparation of composition
[0116] 1-1. Preparation of a mixture derived from Angelica gigas, Cnidium officinalis, and Peony root
[0117] 1-1-1. Preparation of a mixed extract of Angelica gigas, Cnidium officinalis, and Peony root
[0118] The roots of Angelica gigas, the rhizomes of Cnidium officinalis, and the roots of Peony root were each dried in the shade, chopped, and mixed. Then, 10 times the total weight of each herbal medicine was added to the distilled water (1,000 ml of distilled water per 100 g of herbal medicine), and the extract was obtained by boiling and extracting at 95°C for 4 hours. Afterwards, the extracts were combined, concentrated under reduced pressure, and filtered to obtain a mixed extract.
[0119] At this time, the Angelica was selected as either Chinese Angelica or True Angelica, the Cnidium officinalis was selected as either Chinese Cnidium officinalis or Ilchon-gung, and the Peony root was mixed at various weight ratios with the same origin to produce a mixed extract (see Table 1).
[0120]
[0121] 1-1-2. Preparation of polysaccharide isolates from mixed extracts
[0122] Polysaccharide isolates were prepared for each of the mixed extracts prepared in Example 1-1 above.
[0123] Specifically, the mixed extracts prepared in Example 1-1 were taken, 95% ethanol alcohol in an amount four times the volume was added thereto, and the mixture was left to stand at 25°C or lower for 16 hours, and then centrifuged to obtain a precipitated polysaccharide isolate for each mixed extract.
[0124]
[0125] 1-1-3. Preparation of a mixture of mixed extracts and polysaccharide isolates
[0126] A mixture was prepared by mixing the mixed extract prepared in Example 1-1 and the polysaccharide isolate prepared in Example 1-2.
[0127] Specifically, each of the mixed extracts prepared in Example 1-1 and each of the polysaccharide isolates prepared in Example 1-2 were mixed to prepare each mixture. Thereafter, each of the prepared mixtures was filtered through a sterile filter paper (Millipore membrane, 0.45 μm) to maintain sterility.
[0128] At this time, the mixed extract of 1-1 and the polysaccharide isolate of 1-2 were mixed in a weight ratio of 60:40.
[0129]
[0130] All of this is summarized in Table 1 below.
[0131] Experimental group* Angelica gigas, cnidium, and peony ratio Preparation example 1 Chinese Angelica gigas, cnidium, and peony 1:1.6:1.3 Preparation example 2 Chinese Angelica gigas, cnidium, and peony 1:1.5:1.2 Preparation example 3 Chinese Angelica gigas, cnidium, and peony 1:3:3 Preparation example 4 Chinese Angelica gigas, cnidium, and peony 1:1.6:1.3 Preparation example 5 Chinese Angelica gigas, cnidium, and peony 1:1:1 Preparation example 6 Chinese Angelica gigas, cnidium, and peony 1:4:1 Preparation example 7 Chinese Angelica gigas, cnidium, and peony 1:1:4 Preparation example 8 Chinese Angelica gigas, cnidium, and peony 1:3.5:3.5 Preparation example 9 True Angelica gigas, cnidium, and peony 1:1:1 Preparation example 10 True Angelica gigas, cnidium, and peony 1:1.6:1.3 Preparation example 11 True Angelica gigas, cnidium, and peony 1:1.6:1.3
[0132] * Each experimental group, Manufacturing Examples 1 to 11, mixed and extracted Angelica gigas, Cnidium officinalis, and Peony root in the corresponding weight ratio, prepared polysaccharide isolates (ethanol polysaccharides) of each extract, and then mixed the prepared mixed extracts with the polysaccharide isolates. In Table 1, the polysaccharide isolates are not described, but they refer to a mixture in which the polysaccharide isolates are mixed.
[0133] 1-2. Fraction production using a mixture of mixed extracts and polysaccharide isolates
[0134] Fractions of a mixture of mixed extracts of Angelica gigas, Cnidium officinalis, and Paeonia japonica and their polysaccharide isolates were prepared as shown in Table 2 below.
[0135] Specifically, a fraction of the mixture was prepared by mixing the mixed extracts of Chinese Angelica, Chinese Cnidium officinalis, and Peony root of the above Preparation Example 1 and the polysaccharide isolate (ethanol polysaccharide) thereof using water or ethanol as a solvent.
[0136] In addition, a fraction of the mixture was prepared using the same solvent as above for the mixture of the mixed extracts of Chinese Angelica, Chinese Cnidium officinalis, and Peony root of Manufacturing Example 5 and the polysaccharide isolate thereof.
[0137] To summarize, it is as shown in Table 2 below.
[0138] Experimental group: Angelica gigas, cnidium, and peony ratio: Solvent ratio: Fraction of manufacturing example 1: Chinese Angelica gigas, Chinese Cnidium, and Peony 1:1.6:1.3 Water / ethanol. Fraction of manufacturing example 5: Chinese Angelica gigas, Chinese Cnidium, and Peony 1:1:1 Water / ethanol.
[0139] Example 2. Confirmation of immune-enhancing effect in vitro
[0140] 2-1. Confirmation of spleen cell proliferation capacity
[0141] The spleen cell proliferation ability was confirmed for the manufacturing example manufactured in Example 1 above.
[0142] Specifically, after collecting the mouse spleen and extracting splenocytes, 96 wells were prepared and 1 X 10 cells were added per well. 6Cells / ml were calculated and seeded. Afterwards, each sample was diluted in cell medium to a final concentration of 500 μg / ml, treated, and incubated for 36 hours at 37°C and 5% CO2. After 36 hours, WST-8 (Cell viability assay kit) was treated and reacted for 1 hour at 37°C and 5% CO2 in a light-shielded state. After completion of the reaction, the OD value was measured by absorbance at 450 nm, and the measured OD value was calculated to compare the cell proliferation ability value with the control group.
[0143] At this time, PMA 50 ng / ml and ionomycin 2 μg / ml were used as positive controls.
[0144] The results of the spleen cell proliferation ability confirmed for the mixture are shown in Table 3 and Figure 1.
[0145] MeanCon100%p / i268% Manufacturing Example 1150% Manufacturing Example 2130% Manufacturing Example 3130% Manufacturing Example 4147% Manufacturing Example 5108* Manufacturing Example 6128% Manufacturing Example 7132% Manufacturing Example 8132% Manufacturing Example 9125% Manufacturing Example 10121% Manufacturing Example 11113%
[0146] As can be seen in FIG. 1 and Table 3, it was confirmed that the mixtures of Preparation Examples 1 to 3, which mixed Chinese Angelica, Chinese Cnidium officinalis, and Peony, and Preparation Example 4, which mixed Chinese Angelica, Cnidium officinalis, and Peony, were all superior in spleen cell proliferation ability when compared to Preparation Examples 5 to 11, which were mixed at different mixing ratios or did not use Chinese Angelica.
[0147] Among them, in the case of Manufacturing Examples 1 and 4, in which Chinese Angelica, Chinese Cnidium officinalis or Cnidium officinalis and Peony were mixed in a weight ratio of 1:1.6:1.3, the spleen cell proliferation ability increased by about 150%, and compared to Manufacturing Examples 5 to 11, which increased by about 100% to 130%, it was confirmed that the spleen cell proliferation ability was significantly superior, from a minimum of 20% to a maximum of 50%.
[0148] Through this, it can be seen that the mixture made using Chinese angelica, Chinese cnidium or cnidium officinalis and peony has a very excellent effect in enhancing immunity.
[0149]
[0150] 2-2. Confirmation of the level of expression of the spleen cell cytokine TNF-α
[0151] Next, the degree of splenocyte cytokine expression was confirmed for Manufacturing Examples 1 to 9 manufactured in Example 1 above. Among the cytokines, the degree of expression of TNF-α was confirmed as a representative example.
[0152] Specifically, mouse spleens were collected, splenocytes were extracted, and 48 wells were prepared. Afterwards, 1 X 10 6 Cell solution was prepared at a concentration of 10 cells / ml and seeded into 48 wells. Each sample was diluted to a concentration of 500 μg / ml and incubated for 48 hours at 37°C under 5% CO2 conditions. The target antibody of interest was coated onto a 96-well maxi-binding plate, and ELISA was performed. The antibody expression was measured by absorbance at 450 nm. The results were analyzed by comparing the cytokine expression levels due to sample treatment and are presented in Table 4 and Figure 2.
[0153] As a positive control group, PMA 50 ng / ml and ionomycin 2 μg / ml were used in combination.
[0154]
[0155] MeanCon44.5p / i202.655 Manufacturing Example 181.8355 Manufacturing Example 266.612 Manufacturing Example 364.9375 Manufacturing Example 493.4715 Manufacturing Example 547.542 Manufacturing Example 631.1455 Manufacturing Example 757.987 Manufacturing Example 831.7095 Manufacturing Example 926.314
[0156] As a result, as can be confirmed in Table 4 and Figure 2, it was confirmed that the mixtures manufactured using Chinese Angelica, Chinese Cnidium officinalis or Cnidium officinalis and Peony of the present invention, Manufacturing Examples 1 to 4, increased the expression level of TNF-α, a spleen cell cytokine, when compared with Manufacturing Examples 5 to 9 having different mixing ratios.
[0157] Through this, it can be confirmed that the mixture made using Chinese angelica, Chinese cnidium or cnidium officinalis and peony has an excellent effect in enhancing immunity.
[0158]
[0159] 2-3. Confirmation of T cell proliferation efficacy of fractions
[0160] In order to determine which immunologically active fraction was included in the mixture prepared in Example 1-1, the immunostimulating effect of the fraction prepared in Example 1-2 was examined in terms of T cell proliferation. Representative comparisons were made, focusing on the fractions of Preparation Examples 1 and 5.
[0161] Specifically, Jurkat cell line was cultured in RPMI-1640 medium supplemented with 10% FBS and 1% antibiotic / antimycotic. 96 wells were prepared, and 1 X 10 of the above cells were seeded per well. 6 The cells / ml were calculated and seeded. After incubation for 36 hours at 37°C and 5% CO2, each sample was diluted and treated at a concentration of 500 μg / ml. At 47 hours, WST-8 (Cell viability assay kit) was treated and the reaction was performed for 1 hour at 37°C and 5% CO2 in a light-shielded state. After the reaction was completed, the OD value was measured by absorbance at 450 nm and calculated. The cell proliferation ability value was compared with the control group and is shown in Table 5 and Fig. 3.
[0162] Manufacturing Example 1 Manufacturing Example 5 Water layer Ethanol layer Water layer Ethanol layer conp / i 1000 500 250 1000 500 250 1000 500 250 1000 500 250 AVERAGE 100% 132% 125% 154% 130% 119% 135% 115% 91% 90% 80% 73% 99% 100%
[0163] As a result, as can be seen in Table 5 and Fig. 3, it was confirmed that the fraction of Preparation Example 1, which is a mixture of a mixed extract of Chinese Angelica, Chinese Cnidium officinalis, and Peony root in a weight ratio of 1:1.6:1.3 and a polysaccharide isolate (ethanol polysaccharide) thereof, has a significantly superior T cell proliferative ability compared to the fraction of Preparation Example 5 having a different mixing ratio. In particular, it can be confirmed that the water fraction or the ethanol fraction of the mixture of the present invention has a very excellent T cell proliferative ability of 154% and 135%, respectively, when the concentration is 400 to 500 μg / ml.
[0164] Accordingly, among the fractions of Manufacturing Example 1, the water fraction and the ethanol fraction had excellent T cell proliferation ability, and it was confirmed that the water fraction and the ethanol fraction had particularly excellent effects in enhancing immunity.
[0165] Furthermore, the above results confirm that the water fraction and ethanol fraction obtained from the mixture of the present invention exhibit remarkably excellent T cell proliferation ability, which suggests that the mixture of the present invention, which is the source of the above fractions, has excellent immune-enhancing activity.
[0166]
[0167] Example 3. Confirmation of immune-enhancing effect in vivo
[0168] The mixture (HG) of Preparation Example 1, which was prepared by mixing the mixed extracts of Chinese Angelica, Chinese Cnidium officinalis, and Peony root in a ratio of 1:1.6:1.3, which were confirmed to be most effective in Example 2, and mixing the ethanol polysaccharides thereof, was selected to confirm the immune enhancement effect in vivo.
[0169]
[0170] 3-1. Production of immunocompromised animal models
[0171] The experimental animals were 60 Balb / c mice aged 10-11 weeks (male, Dooyeol Biotech, Republic of Korea), and the test period took approximately 3 weeks.
[0172] Specifically, the mice were acclimatized for one week and housed together in cages of up to five mice each, maintaining a temperature of 23 ± 2°C, a humidity of 60% ± 5, and a 12-hour light-dark cycle (light-dark cycle: 8:00 AM to 8:00 PM). After one week, each mouse was assigned to one of the treatment groups based on its body weight.
[0173] The experimental group is as shown in Table 6 below.
[0174] Group n Number CTL (Negative control) 12 CTX (Positive control) 12 HG125 (125 mg / kg of mixture HG prepared by Manufacturing Example 1) 12 HG250 (250 mg / kg of mixture HG of the present invention prepared by Manufacturing Example 1) 12 HG500 (500 mg / kg of mixture HG of the present invention prepared by Manufacturing Example 1) 12
[0175] Next, to prepare an immunocompromised animal model, CTX (Cyclophosphamide) was administered intraperitoneally at 100 mg / kg, and the specific administration method is as shown in Figure 4.
[0176] Specifically, HG was administered orally to the experimental group for 7 days starting 7 days before inducing immunosuppression (before CTX administration).
[0177] For the next 3 days (from the 8th to the 10th day), CTX and the mixture HG prepared in Manufacturing Example 1 were administered simultaneously, and then for the next 8 days (from the 11th to the 18th day), the mixture HG prepared in Manufacturing Example 1 was additionally administered.
[0178] Thereafter, using the immunocompromised animal model manufactured above, the presence or absence of weight gain, blood cell analysis (WBC), NK cell activity (IFN-γ) analysis, spleen H&E staining analysis, and spleen cell cytokines due to the mixture (HG) manufactured in Manufacturing Example 1 of the present invention were sequentially confirmed. The specific results are as follows in Examples 3-2 to 3-5.
[0179] In addition, the spleen cell proliferation ability of Manufacturing Example 1 was confirmed using a normal animal model, as in Examples 3-6.
[0180]
[0181] 3-2. Confirmation of immunosuppression induced by CTX administration and confirmation of body weight and WBC recovery following administration of the mixture (HG) manufactured in Manufacturing Example 1.
[0182] After CTX administration, we first confirmed whether immunosuppression was properly induced through body weight and CBC analysis. Body weight was measured daily.
[0183] As a result, as can be confirmed in Figure 5, body weight loss was observed in all test groups after a total of three administrations of 100 mg / kg of CTX. This suggests that immunosuppression was induced after CTX administration.
[0184] Afterwards, as a result of administering a mixture (HG) of the mixed extracts of Chinese Angelica, Chinese Cnidium officinalis, and Peony root and the polysaccharide isolate (ethanol polysaccharide) prepared in the above Manufacturing Example 1, it was confirmed that body weight recovery occurred more quickly in all test groups compared to the CTX administration group.
[0185]
[0186] Next, complete blood count (CBC) measurements were performed as follows. Specifically, all mice were anesthetized with 1–2% isoflurane before sacrifice, and whole blood was collected from the abdominal aortic vein. Blood was then collected using EDTA lavender tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), and a complete blood count (CBC) analysis was performed on the collected blood using an ADVIA 2120i hematology system (Siemens, Munich, Germany).
[0187] At this time, an increase in WBC indicates immune function activation.
[0188] As a result, as can be seen in Fig. 6, it was confirmed that the WBC significantly decreased in the CTX administration group, indicating that immunosuppression was well achieved. Afterwards, it was confirmed that the WBC count significantly increased in the HG treatment group of Manufacturing Example 1 of the present invention, confirming that the immune function was restored compared to the CTX treatment group.
[0189]
[0190] 3-3. Confirmation of increased NK cell activity in the group administered the mixture manufactured in Manufacturing Example 1.
[0191] In order to confirm the effect on innate immunity in the group administered the mixture manufactured in Manufacturing Example 1, NK cell activity was confirmed.
[0192] The immunocompromised animals prepared in Example 3-1 above were used, and NK cell activity was confirmed by the following method.
[0193] Before sacrifice, all mice were anesthetized with 1–2% isoflurane, and blood samples were collected. 0.8 mL of blood was transferred to a tube containing heparin (JW Pharmaceutical, Seocho, South Korea). After activating the cells, the blood was placed in a tube and gently mixed for less than 1 h at room temperature. The supernatant was then placed in a 96-well plate and incubated at 37°C for 24 h. After incubation, samples were placed in stained plates and IFN-γ expression was analyzed using a Murine NK Activation Kit (NK MAX Bio, Seongnam, South Korea).
[0194] Here, NK cells are known to function in the spleen and bone marrow and regulate innate immunity in the body, and NK cell activity is measured by IFN-γ expression.
[0195] As a result, as can be confirmed in Fig. 7, it was confirmed that IFN-γ expression was rapidly reduced in the CTX administration group, resulting in immunosuppression. However, in contrast, it was confirmed that IFN-γ expression was significantly increased by about 3 times or more in the HG treatment group of Preparation Example 1, which is a mixture of the present invention.
[0196] Through this, it can be confirmed that NK cell activity significantly increases in the HG group of the present invention, thereby significantly increasing innate immunity.
[0197]
[0198] 3-4. Confirmation of recovery of spleen cell density in the group administered the mixture manufactured in Manufacturing Example 1.
[0199] It was confirmed whether the spleen cell density was restored in the group administered with the mixture manufactured in Manufacturing Example 1.
[0200] The immunocompromised animals prepared in Example 3-1 were used, and hematoxylin and eosin staining of the spleen was performed as follows. Specifically, spleen tissue isolated from the mouse was fixed with 10% neutral buffered formalin (Biosesang, Yongin, Republic of Korea), embedded in paraffin, and then sectioned at 3 μm using a Finesse ME microtome (Thermo Fisher Scientific, Massachusetts, USA). The sections were then dried, paraffin removed, washed with distilled water, and stained with a hematoxylin and eosin solution.
[0201] Afterwards, the stained slides were scanned using a microscopic microscope and the white pulp appearance was compared and analyzed.
[0202] At this time, the cell density of white pulp is an important factor in evaluating immune enhancement, and the results are shown in Figures 8a and 8b.
[0203] As can be seen in the above drawing, in the CTX administration group, a large number of dead cells are visible, and it can be confirmed that the cell density is reduced. On the other hand, in the HG administration group of Preparation Example 1, which is a mixture of the present invention, it can be confirmed that the reduced cell density is recovering.
[0204]
[0205] 3-5. Confirmation of increased cytokine expression in the group administered the mixture manufactured in Manufacturing Example 1.
[0206] The spleen cell proliferation ability was confirmed in the group administered the mixture manufactured in Manufacturing Example 1.
[0207] Immunocompromised animals were identified using the animal model prepared in Example 3-1 above, and spleen cytokines were analyzed as follows. At this time, cytokines analyzed were IL-2, IL-4, IFN-γ, and TNF-α.
[0208] Specifically, spleen cells isolated from the spleen tissue of experimental mice were aseptically filtered and plated in RPMI 1640 medium (Gibco, Grand Island, USA) containing 10% FBS (Gibco, Grand Island, USA) and 1% antibiotic and antimycotic (Gibco, Grand Island, USA). The number of cells per well was then 1 X 10 6 Cells were dispensed into 48-well plates in a total volume of 150 μL, calculated as cells / ml. Then, 50 ng / ml Phorbol 12-myristate 13-acetate (MERCK, Darmstadt, Germany) and 2 μg / ml ionomycin (MERCK, Darmstadt, Germany) diluted in RPMI 1640 medium were treated, and the supernatant was incubated at 37°C for 48 h in a 5% CO2 atmosphere. ELISA analysis (R&D Systems, Minneapolis, USA) was performed using the supernatant, and the absorbance at 450 nm was measured. The results are shown in Figure 9, comparing the cytokine expression levels due to the sample treatments.
[0209] Here, cytokines are produced by activated lymphocytes, and an increase in cytokines indicates enhanced immune function.
[0210] As a result, as can be seen in Figure 9, it can be confirmed that the cytokines in the CTX-induced model are equally increased in the test group, showing a correlation.
[0211] In particular, in the HG group of Manufacturing Example 1 of the present invention, it can be confirmed that the expression of all cytokines, i.e., IL-2, IFN-γ, TNF-α, and IL-4, is significantly increased.
[0212]
[0213] 3-6. Confirmation of spleen cell proliferation in the group administered with the mixture manufactured in Manufacturing Example 1
[0214] The spleen cell proliferation ability was confirmed in the group administered the mixture manufactured in Manufacturing Example 1.
[0215] For this experiment, the normal model, not the immunocompromised animal prepared in Example 3-1, was used for confirmation, and the spleen cell proliferation ability was analyzed as follows. Specifically, spleen cells were isolated from the spleen tissue of the experimental mouse, and the spleen was aseptically washed and plated in RPMI 1640 medium (Gibco, Grand Island, USA) containing 10% FBS (Gibco, Grand Island, USA), 1% antibiotic and antifungal agent (Gibco, Grand Island, USA). Then, the number of cells per well was 1 X 10 6 Cells / ml were calculated and dispensed into a 96-well plate so that the total volume was 100 μL. 50 ng / ml Phorbol 12-myristate 13-acetate (MERCK, Darmstadt, Germany), 2 μg / ml ionomycin (MERCK, Darmstadt, Germany), and HG were diluted in RPMI 1640 medium according to concentration and incubated for 35 h at 37°C and 5% CO2, followed by treatment with WST-8 for 1 h and reaction in a light-shielded state. After completion of the reaction, the OD value of 450 nm absorbance was checked using a microplate reader (TECAN, Mannedorf, Swiss) and is shown in Figure 10.
[0216] The spleen is a maturation organ for immune cells, and as the proliferation capacity of spleen cells increases, it means that immune function improves.
[0217] As a result, as can be seen in Fig. 10, it was confirmed that spleen cells significantly proliferated in all test groups of HG of Preparation Example 1, which is a mixture of the present invention.
[0218]
[0219] In summary, the mixture of the mixed extracts of Angelica gigas, Cnidium officinalis and Paeonia lactiflora of the present invention and the ethanol polysaccharide which is a polysaccharide isolate thereof increases immunity, and in particular, when the mixed extracts of Chinese Angelica gigas, Chinese Cnidium officinalis or Cnidium officinalis and Paeonia lactiflora in a ratio of 1:1.6:1.3 are mixed and used, the immunity is increased more effectively, and among them, the effect of significantly increasing NK cell activity and enhancing innate immunity is very excellent, and further, it was confirmed that the water fraction and ethanol fraction of the mixture are very excellent in enhancing immunity.
[0220]
[0221] 3-7. Statistical Analysis
[0222] All of the above data were analyzed using PRISM 7 (Graphpad Software, California, USA). Continuous data are expressed as mean ± SEM. For all groups, consistent variables were compared using Dunnet's multiple comparison test and one-way ANOVA. A p-value of <0.05 was considered statistically significant.
[0223]
[0224] Accordingly, the mixture of the mixed extracts of Angelica gigas, Cnidium officinalis and Paeonia japonica of the present invention and the ethanol polysaccharide thereof or a fraction of the mixture can be utilized as an immune enhancer including innate immunity.
[0225]
[0226] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the claims described below, and their equivalent concepts, rather than the detailed description above.
Claims
1. An immune-enhancing composition comprising a mixture of extracts of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof or a fraction thereof as an active ingredient.
2. A composition according to claim 1, wherein the immunity is innate immunity, acquired immunity, or a combination thereof.
3. In paragraph 1, A composition wherein the above mixed extract is extracted with a solvent selected from the group consisting of water, straight-chain or branched alcohols having 1 to 6 carbon atoms, organic solvents, and mixed solvents thereof.
4. In paragraph 1, A composition wherein the above mixed extract comprises Angelica gigas, Cnidium officinalis and Peony root in a weight ratio of 1:1.2 to 3:1.2 to 3.
5. In paragraph 1, A composition wherein the above mixed extract is a mixed extract of Chinese Angelica, Chinese Cnidium officinalis or Cnidium officinalis and Peony.
6. In paragraph 1, A composition wherein the above polysaccharide isolate is an ethanol polysaccharide.
7. In paragraph 6, A composition wherein the above ethanol is 95% ethanol.
8. In paragraph 1, A composition wherein the fraction is a water fraction or an ethanol fraction of the mixture.
9. In paragraph 8, A composition characterized in that the water fraction or ethanol fraction has T cell proliferative ability.
10. In paragraph 8, A composition characterized in that the water fraction or ethanol fraction has a T cell proliferation ability of 130 to 160% when the concentration is 400 to 500 μg / ml.
11. In paragraph 1, A composition comprising a mixture of extracts of Angelica gigas, Cnidium officinalis and Paeonia lactiflora and a polysaccharide isolate thereof in a ratio of 60 to 70:30 to 40.
12. In paragraph 1, A composition wherein the mixture is included in an amount of 0.001 to 90 wt% based on the total weight of the composition.
13. In paragraph 1, A composition characterized in that the mixture or a fraction thereof increases NK cell activity.
14. In paragraph 1, A composition characterized in that the mixture or a fraction thereof increases body weight, increases WBC count, restores splenocyte density, increases splenocyte proliferation, and increases immune-related cytokines.
15. In paragraph 14, A composition wherein the cytokine is at least one selected from the group consisting of IL-2, IFN-γ, IL-4, IL-10, TNF-α, IL-12, and IL-6.
16. In paragraph 1, A composition wherein the above composition is a food composition.
17. In paragraph 16, The above food composition is a composition manufactured in the form of powder, granules, tablets, capsules, syrup or beverage.
Citation Information
Patent Citations
A health supplement food for immune modulation produced with herbal mixture extracts of panax ginseng, acanthopanacis cortex and korean mountain ginseng adventitious roots
KR1020090126681A
Preparation method for Angelica gigas NAKAI polysaccharide extract and composition containing the same
KR101898387B1
The pharmaceutical composition and its preparationmethod of herb mixture for cancer inhibition, recoveryof immune system and protection of body from oxidativedamage
KR1020040087711A
The fermented samultang extracting method with the function of both anti-oxidation and immunity and the samultang extract using thereof
KR1020170073058A
KR20220161999A
